FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says
You may also be interested in...
Can FDA Do The "Right Thing" On Transparency? Ask A Lawyer
Proposals from agency task force include releasing when applications are submitted and withdrawn along with FDA reasons for refuse-to-file and complete response letters.
FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules
FDA is working on an initiative to fill many of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies
FDA Launches New System To Track Performances of Its Offices
As part of its transparency initiative, agency has introduced FDA-Track, which reports actions taken by more than 100 agency offices.